BREAKING NEWS

On 22nd November 2021, the European Commission granted marketing authorization for
Brukinsa (zanubrutinib) for the treatment of  Waldenström’s macroglobulinemia in adults who have received
at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy.

LEARN MORE

What's new:

Next events: